Form 4: Alkermes Executive Gaffin Executes Stock Sale

Alkermes EVP and CLO David Joseph Gaffin sold 2,034 ordinary shares as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• David Joseph Gaffin, EVP and CLO of Alkermes, Inc., sold 2,034 ordinary shares on May 4, 2026.
• The shares were sold at a price of $33.20 per share.
• Following the transaction, Gaffin retains beneficial ownership of 231,558 ordinary shares.
• The transaction was executed under a Rule 10b5-1 trading plan adopted on November 19, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement, which is a standard administrative procedure for executives.

Positives

• The sale was conducted via a pre-established Rule 10b5-1 plan, indicating the transaction was scheduled in advance rather than based on non-public information.

Negatives

• The transaction represents a reduction in the executive's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market, though this was a planned divestment.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives at major pharmaceutical companies like Alkermes to avoid potential conflicts of interest regarding insider trading regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small fraction of the executive's total holdings.

Key Dates

Keywords

Alkermes, ALKS, Insider Trading, Form 4, Executive Compensation, Biotech